Menu
Contact Us

About Us

We are targeted sequencing experts unlocking the power of LoopCap™ technology for simple, scalable, target enrichment workflows.

Our Mission

At Molecular Loop, we are unlocking the potential of targeted sequencing, making it accessible to any laboratory with our revolutionary LoopCap™ technology. Our aim is to democratize access to the questions that only NGS can answer by providing simple and scalable target enrichment workflows. With our visionary team dedicated to innovation and scientific excellence, we strive to propel discoveries that reshape the frontiers of healthcare and scientific exploration.

Our Leadership

Our leadership team is composed of NGS veterans who are experts in targeted sequencing.

Greg Porreca, Ph.D.

Founder &
Chief Executive Officer

Eric Boyden, Ph.D.

Co-founder &
Chief Scientific Officer

Pat Saunders

President &
Chief Operating Officer

Board of Directors

Paul Brown
Chris McGuinness
Greg Porreca

Advisory Board

Kevin Marks
Brian Krueger

Molecular Loop Technology Timeline

Molecular Loop timeline
Learn more about our technology

Applications

Products

Resources

Company

Contact Us
Twitter Linkedin-in

Molecular Loop and The Molecular Loop logo are trademarks of Molecular Loop Biosciences, Inc.
© 2021 Molecular Loop Biosciences, Inc. All rights reserved.

FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.

Greg Porreca, Ph.D.

Founder & Chief Executive Officer

Greg was previously co-founder and CTO of Good Start Genetics, a genetic testing laboratory acquired by Invitae Corporation (NYSE: NVTA). Greg earned his PhD in Genetics in the lab of George Church at Harvard where he invented and built one of the first next-generation DNA sequencing platforms. He holds a bachelor’s degree in Biology and Computer Science from The College of New Jersey, is a co-author of numerous high-impact publications on genomics technology, and a co-inventor on over 40 issued and pending patents.

In his free time, Greg loves hiking and skiing with his family in the White Mountains of New Hampshire.

Eric Boyden, Ph.D.

Co-Founder & Chief Scientific Officer

Eric previously was Principal Scientist at Invitae Corporation and Good Start Genetics, where he led the development of automated high-throughput genetic assays and analysis algorithms for clinical NGS applications. Eric earned a BS in Molecular Biology at the University of Connecticut and a Ph.D. in Genetics at Harvard University, trained in next-generation sequencing and bioinformatics during a postdoctoral fellowship at Boston Children’s Hospital, has co-authored several gene discovery papers in prominent journals, and is an inventor on several pending or issued patents.

When not working he likes to go camping in western Massachusetts or swimming on Cape Cod with his family.

Pat Saunders

President & Chief Operating Officer

Pat was previously Technical Project Manager at Ovia Health and HighRes Biosolutions and Manager of Laboratory Automation at Good Start Genetics. He has overseen the development and delivery of numerous automated HTP platforms for academic and commercial use around the world. He holds a BS in Neurobiology and Neurosciences from Northeastern University and graduate credit in Computer Science and Business Management from the Harvard Extension School.

Pat spends his free time with his family on Cape Cod and mountain biking in the Green Mountains of Vermont.

Paul Brown, Ph.D.

Board of Directors

Following a post-doctoral fellowship at Caltech, Paul joined Roche in 1986. He held several leadership roles within the pharmaceutical division, including Lifecycle Leader for Tamiflu® and Xenical® in Switzerland, Vice President of Sales and Marketing in Canada, General Manager in Sweden. In 2010 Paul transitioned into the Diagnostics Division as President and Chief Executive Officer of Roche Molecular Diagnostics where he substantially grew its core businesses of virology, blood screening and infectious diseases, while improving the medical value and increasing testing efficiency in the areas of microbiology, oncology and genomics. Before retiring from Roche at the end of 2020 Paul was Head of Roche Molecular Solutions and responsible for the Company’s Molecular Diagnostics, Tissue Diagnostics and Sequencing Solutions Business Units globally. 

Since 2020 Paul has served in an Advisory, or Board capacity to the following organisations: Decheng Capital, Adela, Mammoth Biosciences, End Point Health and Ontera.

Chris McGuiness

Board of Directors

Chris has spent the majority of his career as an entrepreneur and business operator in the life science and telecommunications fields. As Co-Founder and Chief Operating Officer at Kapa Biosystems, Chris helped build the business from the ground up, across multiple offices, until the sale of Kapa to Roche in 2015. Prior to Kapa, Chris was a Co-Founder and director of ECHO, a broadband network engineering firm established in 2000 with offices in Europe and Asia. After growing to 300 employees and 100 million in revenue, Keppel Communications acquired ECHO in 2003. Chris spent the first part of his career as a broadband design and construction manager in Malaysia and Spain.

Kevin Marks

Advisory Board

Kevin Marks currently serves as Chief Legal Officer/General Counsel at the Parker Institute for Cancer Immunotherapy (PICI), where he oversees Legal, Intellectual Property and Human Resources.

Before joining PICI, Marks was General Counsel at the California Institute for Regenerative Medicine (CIRM), where he was responsible for Legal, Human Resources, Grants Management and IT. Marks joined CIRM in 2021 after 14 years at Roche Diagnostics in the therapeutics and diagnostics areas, serving as Vice President and Head of Legal and Compliance at Roche Molecular Solutions (encompassing molecular diagnostics, tissue diagnostics and sequencing) and Vice President and General Counsel at Roche Molecular Diagnostics. In these roles, Marks oversaw teams in general law, employment law, compliance and intellectual property. He also managed the business area’s global litigation portfolio, coordinated legal and compliance support for nine U.S. states, as well as in Europe and Africa, and directed the acquisition and legal integration of six startup companies. Prior to that, Marks served in Roche’s pharmaceutical side for nine years as Vice President, General Counsel at Roche Palo Alto, LLC.

He earned his undergraduate AB degree in International Affairs and Russian at Lafayette College and his law degree at Villanova University.